


## Data Sheet (Cat.No.T12834)

### Saroglitazar Magnesium

#### Chemical Properties

CAS No.:	1639792-20-3
Formula:	C50H56MgN2O8S2
Molecular Weight:	901.42
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



#### Biological Description

Description	Saroglitazar Magnesium is a novel agonist of peroxisome proliferator-activated receptor (PPAR)(predominant PPAR $\alpha$ and moderate PPAR $\gamma$ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively).
Targets(IC <sub>50</sub> )	PPAR $\alpha$ : 0.65 pM (EC <sub>50</sub> , HepG2 cell) PPAR $\gamma$ : 3 nM (EC <sub>50</sub> , HepG2 cell)
In vivo	In db/db mice, Saroglitazar (0.01-3 mg/kg per day, orally) treatment with 12-day causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose.in Wistar rats and marmosets A 90-day repeated dose comparative study confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes.

#### Solubility Information

Solubility	DMSO: 50 mg/mL (55.47 mM) ( < 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

#### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.109 mL	5.547 mL	11.094 mL
5 mM	0.222 mL	1.109 mL	2.219 mL
10 mM	0.111 mL	0.555 mL	1.109 mL
50 mM	0.022 mL	0.111 mL	0.222 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

#### Reference

1. Jain MR, et al. Saroglitazar, a novel PPAR $\alpha$ / $\gamma$  agonist with predominant PPAR $\alpha$  activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:[info@targetmol.com](mailto:info@targetmol.com)

Address:36 Washington Street,Wellesley Hills,MA 02481